United Kingdom (UK)
Recombinant monoclonal antibody to HA. Manufactured using AbAb’s Recombinant Platform with variable regions (i.e. specificity) from the human B-cell clone CR8020.
UniProt Accession Number of Target Protein: P03435; P03437
Alternative Name(s) of Target: Hemagglutinin; Avian Influenza Virus; AIV; H3N2; H7N7; Influenza A virus
Immunogen: The original antibody was generated from the PBMCs of donors vaccinated 7 days earlier with the trivalent inactivated influenza vaccine for the 2006-2007 season (containing A/New Caledonia/20/1999 (H1N1), A/Wisconsin/67/2005 (H3N2), and B/Malaysia/2506/2004).
Specificity: This antibody binds hemaglutinin of most group 2 influenza viruses including H3N2 and H7N7.
Application Notes: CR8020 has a broad neutralizing activity against most group 2 viruses, including H3N2 and H7N7. The crystal structure of Fab CR8020 with the 1968 pandemic H3 hemagglutinin (HA) reveals a highly conserved epitope in the HA stalk distinct from the epitope recognized by the VH1-69 group 1 antibodies. CR8020 binds most group 2 HAs with high affinity, including H3 isolates. Flow cytometry was used to test the ability of the antibody to bind different structural HA conformations of recombinant influenza A subtype H3. Therapeutic treatment with 15 mg/kg of CR8020 up to 2 days after infection with H3N2 completely prevented mortality, whereas 50% of the mice treated 3 days after infection were protected (PMID: 21737702). It is reported that Oseltamivir/Zanamivir may congruously improve the therapeutic efficacy of CR8020 (PMID: 22693576).
Antibody first published in:
Ekiert et al. A highly conserved neutralizing epitope on group 2 influenza a viruses. Science (2011); 333(6044): 843–850. PMID:21737702
Note on publication:
Describes the isolation and characterization of this antibody and further describes its crystal structure.